Edward Kim, MD of Levine Cancer Institute discusses the use of gefitinib versus standard chemotherapy for patients with stage II-IIIA non-small cell lung cancer with an EGFR mutation. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Gefinitib vs vinorelbine-cisplatin as adjuvant treatment in stage II-IIIA NSCLC with EGFR-activating mutation
